Mississippi Just Passed the Boldest Ibogaine Law of 2026. The Vote Was 161 to 2.

Fifty-one to one. One hundred and ten to one.

This is Mississippi. The state that filed Dobbs v. Jackson Women's Health and still bans most abortions. The state that didn't approve a medical marijuana program until 2022 and is not going to legalize recreational marijuana. The state that voted for Donald Trump by more than 20 points in 2024.

And on March 26, both of its legislative chambers sent Republican Governor Tate Reeves a Schedule I psychedelic bill with a combined vote of 161 to 2. He signed it.

When the conservative bulwark moves this far outside its own priors, the question is no longer whether something is happening with ibogaine policy in the United States. The question is what kind of dam this is, and how much of it is already gone.

The default narrative on psychedelic policy says the leading states are Oregon, Colorado, California: these are the same coastal-progressive bloc that legalized cannabis early and decriminalized psilocybin first. That narrative is not wrong, but it is not the story anymore. The boldest ibogaine bill of 2026 came from Mississippi, and almost no one outside the state covered it.

What HB 314 actually does

The bill, sponsored by Rep. Sam Creekmore IV (R), chairman of the House Public Health and Human Services Committee, directs the Mississippi State Department of Health to establish a research consortium of three required members: a drug developer, an institution of higher learning, and a hospital. The legislature appropriates $5 million from the state's opioid settlement funds to seed the work. A pharmaceutical company or third party must match the appropriation. The mandate is FDA approval of ibogaine as a treatment for opioid use disorder, co-occurring substance use disorder, and "any other neurological or mental health condition for which ibogaine demonstrates efficacy."

The bill assigns 20% of any intellectual property revenue generated by the trials to Mississippi's general fund. The law takes effect July 1.

Read it plainly: the state of Mississippi is now in the ibogaine drug development business, with a structured revenue claim on eventual approval, a hospital-and-university partnership requirement that locks in clinical legitimacy, and a research target that explicitly includes the addiction crisis devastating its rural counties.

Why it passed: the answer that's actually interesting

Mississippi has Camp Shelby. It has Naval Air Station Meridian. It has Keesler Air Force Base. It has a high per-capita rate of military service, and it has a generation of post-9/11 veterans who came home with traumatic brain injuries, treatment-resistant PTSD, and addiction profiles the VA has not been able to fix. Veterans groups testified for HB 314. Veterans groups reach Republican legislators in Mississippi the way climate scientists reach Democratic legislators in California: through trust the other coalition does not have.

It also has fentanyl. The funding source for HB 314 is not the general fund, it is the state's opioid settlement money. The same dollars that compensated Mississippi for the opioid crisis are now paying for the trial that aims to fix it. That's not a coincidence. It's the bill's argument.

The third piece is the harder one. In states where public confidence in federal scientific institutions is low (Mississippi is one of them), "the FDA hasn't approved this" reads as a reason, not a warning. The same sentence carries opposite weight in the two political environments. The absence of FDA approval, which paralyzes the conversation in blue states, accelerates it in red ones. There is no progressive harm-reduction base demanding boutique purity. There is no establishment-medicine base treating regulatory absence as a debate-ender. The result is faster, cleaner consensus around veterans and overdose response than anywhere on the coasts.

The 161-to-2 margin is not Mississippi exceptionalism. It is what bipartisan-on-veterans-and-fentanyl looks like when the cultural war that paralyzes the same conversation in blue states is absent. And Mississippi is not the only state where that cultural war is absent.

The pattern, not the headline

Multiple states are now in motion. Oregon legalized ibogaine under a regulated framework in February. Colorado established a research pilot in March. Mississippi appropriated $5 million the same month. Texas committed $50 million to UTHealth Houston and UTMB in late March for a two-year clinical trial focused on addiction and TBI. More bills are working through state legislatures right now.

The federal pathway is, for the moment, irrelevant to most of this. The Trump executive order on psychedelics in April directed the FDA to accelerate review and instructed the DEA and FDA to establish a Right to Try pathway specifically including ibogaine. None of the state-level activity above was waiting for that order. None of it is conditional on it. The trials Mississippi just funded will run regardless of what the FDA does in 2027.

If the most conservative legislature in the country can pass an ibogaine bill 161 to 2, every other state legislature can. That isn't speculation about red states or blue states. It is what the math says when you remove the assumption that the next ibogaine vote has to look like Oregon's.

The question for anyone watching this — veterans, families of people in active addiction, the small Mexico clinics that have been the only legal access for a decade — is not whether ibogaine treatment becomes available in the United States.

It's how soon, and how many states get there before Washington does.